CourageGT

CourageGT is a pre-clinical stage biotechnology company focused on developing transformative gene therapies for rare, monogenic diseases. Founded by pioneers in the adeno-associated virus (AAV) field from UMass Chan Medical School, the company leverages advanced viral vector technology to deliver therapeutic genes to target tissues. Its lead program targets Friedreich's Ataxia, aiming to restore frataxin protein levels and address the underlying cause of the neurodegenerative and hypertrophic cardiomyopathy symptoms. CourageGT is dedicated to advancing its pipeline through rigorous research and strategic collaborations to bring life-changing treatments to patients with high unmet medical needs. The company's platform emphasizes optimized capsids and promoters to improve the safety and efficacy of gene delivery.